This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Veliparib

AbbVie Inc.

Drug Names(s): ABT-888, Velaparib

Description: ABT-888 is an orally active inhibitor of Poly (ADP-ribose) Polymerase (PARP). PARP is involved in rescuing tumor cells from DNA damage mediated by chemotherapy, making it a target for oncology treatments. Pharmacologic blockade of the PARP cell death pathway also prevents oxidant-mediated cell death and organ dysfunction, making it a target for diseases mediated by cell necrosis, DNA repair abnormality, and inflammation.

Deal Structure: AbbVie and Myriad
In November 2014, AbbVie and Myriad Genetics signed an expanded companion diagnostic agreement with AbbVie to use Tumor BRACAnalysis CDx as a companion diagnostic in support of AbbVie's novel poly (ADP-ribose) polymerase or PARP inhibitor, veliparib.

In February 2016, Myriad Genetics expanded the companion diagnostics (CDx) research collaboration with AbbVie to support the development of AbbVie's investigational PARP inhibitor, veliparib. Under the terms of the agreement, AbbVie will use Myriad's CDx portfolio myChoice HRD and new tumor tests to help identify patients with non-small cell lung cancer who are likely to respond to treatment with the combination of veliparib and chemotherapy. Other terms of the deal were not disclosed.


Veliparib News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug